Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;29(1):101-102.
doi: 10.1016/j.tracli.2021.07.006. Epub 2021 Jul 29.

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma

Massimo Franchini  1 , Fausto Baldanti  2 , Elena Percivalle  2 , Alessandro Ferrari  2 , Pietro Biasi  3 , Giancarlo Maria Liumbruno  3 , Claudia Glingani  3
Affiliations
Comment

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma

Massimo Franchini et al. Transfus Clin Biol. 2022 Feb.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a. Pre- and post-amotosalen + UVA PRT treatment and anti-SARS-Cov-2 neutralizing antibody titer. b. Box-plot diagram showing pre- and post-amotosalen + UVA PRT treatment and anti-SARS-Cov-2 neutralizing antibody titer. The comparison between the two boxes (right and left) shows a substantial equivalence in terms of variability and distribution of the pre- and post-PRT treatment values. The bold horizontal black bar indicates the median values, while the width of the box indicates the distance between the first and the third quartile of the distribution.
See this image and copyright information in PMC

Comment on

References

    1. Focosi D., Franchini M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol. 2021;28:132–134. - PMC - PubMed
    1. Azhar E.I., Hindawi S.I., El-Kafrawy S.A., Hassan A.M., Tolah A.M., Alandijany T.A., et al. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang. 2020 doi: 10.1111/vox.13043. - DOI - PMC - PubMed
    1. Yonemura S., Hartson L., Dutt T.S., Henao-Tamayo M., Goodrich R., Marschner S. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology. Vox Sang. 2021;9 doi: 10.1111/vox.13108. - DOI - PMC - PubMed
    1. Kostin A.I., Lundgren M.N., Bulanov A.Y., Ladygina E.A., Chirkova K.S., Gintsburg A.L., et al. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. Vox Sang. 2021;18 doi: 10.1111/vox.13056. - DOI - PMC - PubMed
    1. Perotti C., Baldanti F., Bruno R., Del Fante C., Seminari E., Casari S., et al. Covid-Plasma Task Force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020;105:2834–2840. - PMC - PubMed